Lyell Immunopharma's total assets for Q1 2025 were $429.80M, a decrease of -12.44% from the previous quarter. LYEL total liabilities were $93.28M for the fiscal quarter, a -13.66% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.